Rena Buckstein

9.5k total citations · 2 hit papers
191 papers, 5.1k citations indexed

About

Rena Buckstein is a scholar working on Hematology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, Rena Buckstein has authored 191 papers receiving a total of 5.1k indexed citations (citations by other indexed papers that have themselves been cited), including 99 papers in Hematology, 80 papers in Genetics and 70 papers in Pathology and Forensic Medicine. Recurrent topics in Rena Buckstein's work include Acute Myeloid Leukemia Research (85 papers), Lymphoma Diagnosis and Treatment (70 papers) and Chronic Lymphocytic Leukemia Research (35 papers). Rena Buckstein is often cited by papers focused on Acute Myeloid Leukemia Research (85 papers), Lymphoma Diagnosis and Treatment (70 papers) and Chronic Lymphocytic Leukemia Research (35 papers). Rena Buckstein collaborates with scholars based in Canada, United States and Italy. Rena Buckstein's co-authors include Richard A. Wells, Michael J. Rauh, Hagop M. Kantarjian, Mark D. Minden, Kevin Imrie, Richard A. Wells, Matthew C. Cheung, Michael Crump, Brooke Snetsinger and David Spaner and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Rena Buckstein

181 papers receiving 5.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

2012 818 citations Hagop M. Kantarjian, Xavier Thomas et al. Journal of Clinical Oncology profile →
Identification of miR-145 and miR-146a as mediators of the 5q– syndrome phenotype

2009 507 citations Richard A. Wells, Rena Buckstein et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rena Buckstein Canada	33	2.5k	1.6k	1.6k	1.5k	1.4k	191	5.1k
Bernhard Wörmann Germany	40	3.3k 1.3×	1.9k 1.2×	1.5k 1.0×	1.9k 1.3×	1.6k 1.1×	173	6.3k
Joseph O. Moore United States	42	3.3k 1.3×	1.8k 1.1×	1.5k 0.9×	1.9k 1.3×	997 0.7×	148	6.6k
Thomas Pabst Switzerland	30	2.5k 1.0×	1.6k 1.0×	713 0.4×	1.2k 0.8×	738 0.5×	180	4.3k
Sigurður Y. Kristinsson Sweden	46	3.9k 1.6×	2.2k 1.4×	2.6k 1.6×	1.6k 1.1×	834 0.6×	142	6.0k
Ulrike Bacher Germany	39	4.1k 1.7×	1.8k 1.1×	2.1k 1.3×	1.1k 0.7×	622 0.4×	281	5.7k
Monique C. Minnema Netherlands	39	2.9k 1.2×	1.8k 1.2×	1.6k 1.0×	2.1k 1.4×	1.2k 0.8×	229	5.6k
Dominique Bordessoule France	39	2.3k 0.9×	1.3k 0.8×	1.9k 1.2×	2.2k 1.5×	2.3k 1.6×	188	6.3k
G. Verhoef Belgium	35	1.7k 0.7×	951 0.6×	1.1k 0.7×	1.5k 1.0×	1.4k 1.0×	103	4.4k
Yago Nieto United States	34	1.9k 0.7×	859 0.5×	644 0.4×	1.7k 1.2×	594 0.4×	242	4.0k
Bruno Varet France	37	4.1k 1.6×	1.7k 1.0×	2.6k 1.7×	1.4k 1.0×	1.1k 0.8×	145	7.6k

Countries citing papers authored by Rena Buckstein

Since Specialization

Citations

This map shows the geographic impact of Rena Buckstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rena Buckstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rena Buckstein more than expected).

Fields of papers citing papers by Rena Buckstein

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rena Buckstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rena Buckstein. The network helps show where Rena Buckstein may publish in the future.

Co-authorship network of co-authors of Rena Buckstein

This figure shows the co-authorship network connecting the top 25 collaborators of Rena Buckstein. A scholar is included among the top collaborators of Rena Buckstein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rena Buckstein. Rena Buckstein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sabloff, Mitchell, et al.. (2024). Developing Organizational Requirements to Standardize Delivery and Improve Quality of Acute Leukemia Care in Ontario. Current Oncology. 31(8). 4656–4674. 1 indexed citations

Buckstein, Rena, Jeannie Callum, Anca Prica, et al.. (2024). Red cell transfusion thresholds in outpatients with myelodysplastic syndromes: Results of a pilot randomized trial RBC‐ENHANCE. Transfusion. 64(2). 223–235. 1 indexed citations

Platzbecker, Uwe, Valeria Santini, Rami S. Komrokji, et al.. (2023). Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts. Leukemia. 37(11). 2314–2318. 7 indexed citations

Buckstein, Rena, Karen Yee, Michelle Geddes, et al.. (2023). The burden of red blood cell transfusions in patients with lower-risk myelodysplastic syndromes and ring sideroblasts: an analysis of the prospective MDS-CAN registry. Leukemia & lymphoma. 64(3). 651–661. 3 indexed citations

Mozessohn, Lee, Ning Liu, Brian Leber, et al.. (2023). Impact of Frailty on Health Care Resource Utilization and Costs of Care in Myelodysplastic Syndromes. JCO Oncology Practice. 19(4). e559–e569. 3 indexed citations

Ravindran, Mithunan, et al.. (2023). A Markov analysis of azacitidine and venetoclax vs induction chemotherapy for medically fit patients with AML. Blood Advances. 8(3). 629–639. 1 indexed citations

Cook, Elina K., et al.. (2017). Feeding the Fire: The Comorbid and Inflammatory Backdrop of Clonal Hematopoiesis of Indeterminate Potential (CHIP) By Mutation Subtype. Blood. 130. 426–426. 6 indexed citations

Vijenthira, Abi, Richard A. Wells, Jeannie Callum, et al.. (2017). Rates of Severe Bleeding Are Low in Patients with MDS and Severe Thrombocytopenia and May be Mitigated By Tranexamic Acid. Blood. 130. 1691. 1 indexed citations

Cull, Alyssa, Brooke Snetsinger, Rena Buckstein, Richard A. Wells, & Michael J. Rauh. (2017). Tet2 restrains inflammatory gene expression in macrophages. Experimental Hematology. 55. 56–70.e13. 222 indexed citations

10.

Santini, Valeria, António Almeida, Aristoteles Giagounidis, et al.. (2017). The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes: Results From the MDS-005 Study. Clinical Lymphoma Myeloma & Leukemia. 18(2). 136–144.e7. 15 indexed citations

11.

Cheung, Matthew C., et al.. (2016). Granulocyte colony-stimulating factor in secondary prophylaxis for advanced-stage Hodgkin lymphoma treated with ABVD chemotherapy: a cost-effectiveness analysis. Leukemia & lymphoma. 57(8). 1865–1875. 2 indexed citations

12.

Timilshina, Narhari, Henriette Breunis, Joseph Brandwein, et al.. (2014). Do quality of life or physical function at diagnosis predict short-term outcomes during intensive chemotherapy in AML?. Annals of Oncology. 25(4). 883–888. 17 indexed citations

13.

Kantarjian, Hagop M., Xavier Thomas, Anna Dmoszyńska, et al.. (2012). Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia. Journal of Clinical Oncology. 30(21). 2670–2677. 818 indexed citations breakdown →

14.

Breunis, Henriette, Narhari Timilshina, Joseph Brandwein, et al.. (2012). Older age is associated with similar quality of life and physical function compared to younger age during intensive chemotherapy for acute myeloid leukemia. Leukemia Research. 36(10). 1241–1248. 42 indexed citations

15.

Zinzani, Pier Luigi, Nuriet K. Khuageva, Huaqing Wang, et al.. (2012). Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial. Journal of Hematology & Oncology. 5(1). 67–67. 17 indexed citations

16.

Witzig, Thomas E., Julie M. Vose, Pier Luigi Zinzani, et al.. (2011). An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma. Annals of Oncology. 22(7). 1622–1627. 300 indexed citations

17.

Buckstein, Rena, John Kuruvilla, Neil Chua, et al.. (2011). Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group. Leukemia & lymphoma. 52(5). 833–841. 14 indexed citations

18.

Imrie, Kevin, et al.. (2011). High-dose methotrexate based chemotherapy with deferred radiation for treatment of newly diagnosed primary central nervous system lymphoma. Leukemia & lymphoma. 52(10). 1882–1890. 13 indexed citations

19.

Mangel, Joy, Heather A. Leitch, Joseph M. Connors, et al.. (2004). Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis. Annals of Oncology. 15(2). 283–290. 76 indexed citations

20.

Allan, David, Rena Buckstein, & Kevin Imrie. (2001). Outpatient Supportive Care Following Chemotherapy for Acute Myeloblastic Leukemia. Leukemia & lymphoma. 42(3). 339–346. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact